



		Agenda Ite	em No:	13			
Report to:	ICB Board						
Date of Meeting:	13 September 2023						
Subject:	Clinical & Professional Update						
Director Sponsor:	Dr Nigel Wells, Executive Director for Clinical & Professional						
Author:	Dr Nigel Wells, Executive Director for Clinical & Professional						
STATUS OF THE REPORT: (Please click on the appropriate box) Approve Discuss Assurance Information A Regulatory Requirement							
SUMMARY OF REPORT: This report provides an update on key areas of focus within the Clinical and Professional directorate. An overview is given on the MMR vaccination campaign, a progress update on establishing the HNY IRIS function and an outline of the work to review clinical policies, particularly those procedures identified as having limited clinical value.							
RECOMMENDATIO	NS:						
Members are asked to:							
 Note the updates provided on the MMR vaccination campaign, IRIS and clinical policies. 							
ICB STRATEGIC OBJECTIVE (please click on the boxes of the relevant strategic objective(s)							
Managing Today			\boxtimes				
Managing Tomorrow			\boxtimes				
Enabling the Effective Operation of the Organisation							
IMPLICATIONS (Ple	ase state N/A against any domain where none are	identified)					
Finance		The financial implications for clinical policy workstreams will be fully developed, to inform the recommendations and decision-making process.					
Quality	Quality Committee via the members	The Clinical & Professional Committee has a direct link to the Quality Committee via the membership of the chair (Executive Director Clinical & Professional) and vice chair (Executive Director Quality & Nursing).					

HR	N/A
Legal / Regulatory	The Clinical and Professional Executive Committee forms part of the formal governance structure of the ICB.
Data Protection / IG	N/A
Health inequality / equality	The Clinical and Professional Executive Committee has a focus on improving population health, including health inequalities. All emerging Clinical Policies are subject to an Equalities and Health Inequalities Impact Assessment.
Conflict of Interest Aspects	Conflicts of Interest at Clinical and Professional Executive Committee are managed in line with the ICB Conflicts of Interest policy
Sustainability	N/A

ASSESSED RISK:

Risks will be identified and assessed for individual workstreams within this update and will inform the proposed recommendations and decision-making. All risks will then be monitored by the Clinical & Professional Executive Committee.

MONITORING AND ASSURANCE:

Recommendations will be monitored by the Clinical & Professional Executive Committee.

ENGAGEMENT:

The Clinical and Professional Group is a key forum utilised to engage with clinical and care professionals across the ICB. The Clinical and Professional Executive will be engaged and has a decision making role in respect of the clinical policies adopted by the ICB. Additional engagement will take place where necessary, including through the Ethics Panel.

REPORT EXEMPT FROM PUBLIC DISCLOSURE	No	\boxtimes	Yes	
If yes, please detail the specific grounds for exemption.				